Integrated Investment Consultants LLC Lowers Position in Amgen Inc. (NASDAQ:AMGN)

Integrated Investment Consultants LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,739 shares of the medical research company’s stock after selling 87 shares during the period. Integrated Investment Consultants LLC’s holdings in Amgen were worth $714,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Capital Performance Advisors LLP bought a new position in shares of Amgen in the third quarter worth approximately $25,000. Legacy Investment Solutions LLC purchased a new position in Amgen during the third quarter valued at $29,000. Hershey Financial Advisers LLC bought a new stake in Amgen in the 2nd quarter valued at $30,000. Matrix Trust Co purchased a new stake in Amgen in the 3rd quarter worth $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen during the 3rd quarter valued at about $56,000. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on AMGN. Royal Bank of Canada reduced their target price on Amgen from $360.00 to $330.00 and set an “outperform” rating on the stock in a report on Wednesday, November 27th. Citigroup reduced their price objective on Amgen from $335.00 to $310.00 in a research note on Wednesday, November 27th. Jefferies Financial Group reiterated a “buy” rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Finally, Redburn Partners decreased their price target on shares of Amgen from $200.00 to $195.00 in a research note on Wednesday, November 27th. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $314.91.

Amgen Stock Up 1.0 %

Shares of AMGN opened at $272.11 on Friday. The firm has a market capitalization of $146.27 billion, a P/E ratio of 34.84, a P/E/G ratio of 2.68 and a beta of 0.56. Amgen Inc. has a 12-month low of $253.30 and a 12-month high of $346.85. The firm has a fifty day moving average price of $275.01 and a 200-day moving average price of $307.49. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analysts’ expectations of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The firm’s quarterly revenue was up 23.2% on a year-over-year basis. During the same period in the previous year, the company earned $4.96 EPS. Equities research analysts expect that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.50%. The ex-dividend date is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.